Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vir BiotechnologyVIR +0.96%52 6-1 Month Momentum % is 20.43% as of Aug. 19, 2026. GuruFocus rates VIR with a GF Score™ of 52/100 and a GF Value™ of $42.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,378 Biotechnology companies, Vir Biotechnology ranks better than 82.29% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-19), Vir Biotechnology's 6-1 Month Momentum % is 20.43%.
The industry rank for Vir Biotechnology's 6-1 Month Momentum % or its related term are showing as below:
VIR's 6-1 Month Momentum % is ranked better than 82.29% of 1378
companies
in the Biotechnology industry
Industry Median: -14.265
vs VIR: 20.43
Vir Biotechnology (NAS:VIR) 6-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vir Biotechnology 6-1 Month Momentum % Related Terms
VIR vs AVBP, XNCR, SEPN: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Vir Biotechnology's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's 6-1 Month Momentum % falls into.
Vir Biotechnology (NAS:VIR) 6-1 Month Momentum % Calculation
6-1 Month Momentum % is calculated as following:
6-1 Month Momentum %
=
( Price 1-month ago
/
Price 6-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (VIR) has a 6-1 Month Momentum % of 20.43% as of Aug. 19, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vir Biotechnology and its competitors. According to the industry distribution chart, Vir Biotechnology ranks #244 out of 1378 companies in the Biotechnology industry, placing it in the top 17.7%.
Is Vir Biotechnology's 6-1 Month Momentum % too high?
Vir Biotechnology's current 6-1 Month Momentum % is 20.43%. Based on the distribution chart, Vir Biotechnology ranks #244 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vir Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's 6-1 Month Momentum % compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #244 out of 1378 companies for 6-1 Month Momentum %. This places Vir Biotechnology in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current 6-1 Month Momentum % is 20.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.26, compared to a current price of $9.50 — trading 77.5% below its estimated fair value. The current 6-1 Month Momentum % is 20.43%. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current 6-1 Month Momentum % is 20.43% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.26.
GuruFocus considers Vir Biotechnology to be Possible Value Trap.
Key valuation signals for VIR:
6-1 Month Momentum %: 20.43%
GF Value™: $42.26 vs. price of $9.50 (77.5% below fair value)
No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for VIR
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIR has been successfully added to your 
